NaNotics

NaNotics is a mature preclinical-stage company focused on the development and commercialization of NaNots™. NaNots™, a novel subtractive nanoparticle, treat diseases by capturing and removing pathogenic molecules from the blood for use in treating serious illnesses in humans and their companion animals. The company leverages multiple suppliers and co-development relationships, particularly in the design of nanofabrication and capture agents. NaNotics is developing a product line of eight NaNots™ targeting a range of inflammatory and inhibitory targets that drive various diseases.